Cerenome, Inc. (CNSY)
2.21
-0.12
(-4.95%)
USD |
NASDAQ |
Sep 14, 11:03
Cerenome Enterprise Value : 8.453M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 8.453M |
| September 10, 2026 | 8.928M |
| September 09, 2026 | 9.659M |
| September 08, 2026 | 11.19M |
| September 04, 2026 | 11.60M |
| September 03, 2026 | 13.24M |
| September 02, 2026 | 12.95M |
| September 01, 2026 | 11.27M |
| August 31, 2026 | 12.07M |
| August 28, 2026 | 13.75M |
| August 27, 2026 | 14.12M |
| August 26, 2026 | 13.53M |
| August 25, 2026 | 14.01M |
| August 24, 2026 | 13.09M |
| August 21, 2026 | 13.90M |
| August 20, 2026 | 13.39M |
| August 19, 2026 | 14.78M |
| August 18, 2026 | 13.97M |
| August 17, 2026 | 14.85M |
| August 14, 2026 | 18.36M |
| August 13, 2026 | 18.50M |
| August 12, 2026 | 18.50M |
| August 11, 2026 | 19.45M |
| August 10, 2026 | 19.53M |
| August 07, 2026 | 19.45M |
| Date | Value |
|---|---|
| August 06, 2026 | 19.67M |
| August 05, 2026 | 20.04M |
| August 04, 2026 | 20.40M |
| August 03, 2026 | 17.19M |
| July 31, 2026 | 19.75M |
| July 30, 2026 | 18.14M |
| July 29, 2026 | 17.99M |
| July 28, 2026 | 18.94M |
| July 27, 2026 | 18.72M |
| July 24, 2026 | 19.45M |
| July 23, 2026 | 19.09M |
| July 22, 2026 | 19.38M |
| July 21, 2026 | 20.11M |
| July 20, 2026 | 19.45M |
| July 17, 2026 | 18.80M |
| July 16, 2026 | 19.97M |
| July 15, 2026 | 21.28M |
| July 14, 2026 | 22.74M |
| July 13, 2026 | 21.94M |
| July 10, 2026 | 20.70M |
| July 09, 2026 | 20.70M |
| July 08, 2026 | 19.38M |
| July 07, 2026 | 20.11M |
| July 06, 2026 | 21.06M |
| July 02, 2026 | 20.55M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ernexa Therapeutics, Inc. | 0.1951M |
| ACADIA Pharmaceuticals, Inc. | 3.908B |
| Alnylam Pharmaceuticals, Inc. | 32.94B |
| Anika Therapeutics, Inc. | 266.01M |
| Savara, Inc. | 945.99M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.006M |
| Revenue (Quarterly) | 0.411M |
| Total Expenses (Quarterly) | 9.417M |
| EPS Diluted (Quarterly) | -1.305 |
| Gross Profit Margin (Quarterly) | 63.26% |
| Profit Margin (Quarterly) | -2.19K% |
| Earnings Yield | -199.5% |
| Normalized Earnings Yield | -199.54 |